Presentations

2025

CTAD Dec 3, 2025

Regulatory Role of Semaphorin 4D in the Nervous System

Presented by M. Zauderer, Ph.D.

SITC Nov 7, 2025

Neoadjuvant pepinemab enhances immune checkpoint blockade in metastatic melanoma

Presented by Crystal Mallow

AAIC July 28, 2025

Targeting SEMA4D/PLXN signaling through reactive glia as a common pathology for the treatment of neurodegenerative disorders

Presented by T. Fisher, Ph.D.

ASCO June 4, 2025

Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer

Presented by Conor E. Steuer M.D.

AACR8172 April 25, 2025

Regulating dendritic cells to promote mature tertiary lymphoid structures and enhance anti-tumor immunity

Presented by E. Evans, Ph.D.

AACR6007 April 25, 2025

Neoadjuvant pepinemab enhances DC function associated with mature tertiary lymphoid structures and activity of immune checkpoint blockade in patients with metastatic melanoma

Presented by E. Evans, Ph.D.

AdvTher. Xchange April 14, 2025

Antigen Virions for Antibody Discovery Against Transmembrane Proteins

Presented by Ernest Smith, Ph.D.

AD/PD25 April 5, 2025

Results of SIGNAL-AD, a Randomized Phase 1B/2 Trial Evaluating Safety and Efficacy of Pepinemab in AD

Presented by E. Evans, Ph.D.

2024

SITC Nov 7, 2024

Discovery of High Affinity Antibodies Specific for CXCR5, P2X7 and Other Multi-pass Membrane Receptors

Presented by Ernest Smith, Ph.D.

SITC Nov 5, 2024

Pepinemab a Semaphorin 4D blockade antibody in combination with immune checkpoint therapies...

Presented by Crystal Mallow

CTAD Oct 31, 2024

Results of SIGNAL-AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of pepinemab, anti-SEMA4D antibody...

Presented by E. Evans, Ph.D.

CICON Sept 10, 2024

Inhibition of Semaphorin 4D induces lymphoid aggregates, correlating with clinical outcomes when combined with immune checkpoint therapy

Presented by Crystal Mallow

AAIC July 31, 2024

Results of SIGNAL-AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab...

Presented by Eric Siemers, M.D.

ASCO June 1, 2024

Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate Pepinemab in Combination with Pembrolizumab

Presented by E. Evans Ph.D.

AD/PD April 25, 2024

Targeting Neuroinflammation to Modulate Reactive Astrocytes for Treatment of Neurodegenerative Disease

Presented by E. Evans, Ph.D.

Festival of Biololgics April 16, 2024

Discovery of High Affinity Functional Antibodies Specific for CXCR5 and Other Multi-pass Membrane Proteins

Presented by Ernest Smith, Ph.D.

2023

CTAD Oct 26, 2023

Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease...

Presented by T. Fisher, Ph.D.

Keystone Oct 4, 2023

Inhibition of Semaphorin 4D in combination with immune checkpoint therapy induces organized lymphoid structures ...

Presented by Crystal Mallow

AACR PDAC Sept 27, 2023

A phase 1b/2 trial of pepinemab and avelumab as second line immunotherapy for patients with chemotherapy-refractory metastatic pancreatic adenocarcinoma

Presented by Luis Ruffolo, M.D.

DOT Sept 26, 2023

Discovery of High-Affinity Functional Antibodies Specific for CXCR5 and Other Multi-Pass Membrane Proteins

Presented by Ernest Smith, Ph.D.

DOT Aug 30, 2023

Discovery of High-Affinity Functional Antibodies Specific for CXCR5 and Other Multi-Pass Membrane Proteins

Presented by Ernest Smith, Ph.D.

ASCO June 5, 2023

Phase 1b/2 trial of pepinemabplus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma

Presented by Luis Ruffolo, M.D.

PEGS May 15, 2023

Native complex membrane antigen expression on poxvirus for antibody discovery

Presented by Maria Scrivens

Corporate April 26, 2023

Pepinemab– Anti-SEMA4D Antibody for Neurodegenerative Disease and Cancer Immunotherapy

Presented by M. Zauderer, Ph.D.

Corporate Jan 10, 2023

Pepinemab– Anti-SEMA4D Antibody for Neurodegenerative Disease and Cancer Immunotherapy

Presented by M. Zauderer, Ph.D.

2022

SITC Nov 11, 2022

Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma

Presented by Brian Olson, Ph.D.

SITC Nov 10, 2022

Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer

Presented by Hyo S. Han, Ph.D.

HSB Nov 4, 2022

Synthesis of key results and conclusions of the SIGNAL phase 2 study of pepinemabas a treatment for early HD

Presented by M. Zauderer, Ph.D.

EHDN Sept 16, 2022

Synthesis of key results and conclusions of the SIGNAL phase 2 study of pepinemabas a treatment for early HD

Presented by E. Evans, Ph.D.

ESMO Sept 13, 2022

Neoadjuvant Pepinemab in Combination with Nivolumab and/or Ipilimumab in Resectable Stage III Melanoma

Presented by Michael Lowe, M.D.

Corporate June 10, 2022

Pepinemab– Anti-SEMA4D Antibody for Cancer Immunotherapy

Presented by M. Zauderer, Ph.D.

PEGS May 2, 2022

Native complex membrane antigen expression on poxvirus for antibody discovery

Presented by A. Moksa-Cornelison

Corporate April 27, 2022

Pepinemab– Anti-SEMA4D Antibody for Cancer Immunotherapy and Neurodegenerative Disease

Presented by M. Zauderer, Ph.D.

AACR April 11, 2022

Phase 1/2 study of pepinemab, an inhibitor of semaphorin4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer

Presented by T. Fisher, Ph.D.

AAN April 2, 2022

Clinical evidence that treatment with pepinemab, a novel regulator of neuroinflammation, may provide cognitive benefit to patients with Huntington’s and potentially other neurodegenerative diseases

Presented by E. Evans, Ph.D.

CHDI March 2, 2022

Combination of anti-semaphorin4D immunotherapy and ASO-mediated total HTT lowering provide benefit beyond either individual therapy in humanied HD mice

Presented by Yuanyun Xie, Ph.D.

HNSCC Symposium Feb 24, 2022

Phase 1/2 study of pepinemabin combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84)

Presented by T. Fisher, Ph.D.

Corporate Feb 7, 2022

Pepinemab– Anti-SEMA4D Antibody for Cancer Immunotherapy and Neurodegenerative Disease

Presented by M. Zauderer, Ph.D.

Corporate Jan 5, 2022

Pepinemab– Anti-SEMA4D Antibody for Neurodegenerative Disease and Cancer Immunotherapy

Presented by M. Zauderer, Ph.D.

Presentations

2025

2024

2023

2022

Science

Clinical Trials

ActivMab

Investors and Media